

March 19, 2025

BSE Limited

Corporate Relation Department Phiroze Jeejeebhoy Towers, Dalal Street,

Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department

Exchange Plaza, C-1, Block-G,

Bandra-Kurla Complex,

Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Press Release

Marksans Pharma Limited's wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.

For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd.